| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2025―May―02 |
Sharing Our Experience with Our First Post-COVID-19 Pandemic FDA GCP Inspection","COVID-19 パンデミック後のFDA によるGCP査察の受け入れ経験の共有 |
Akiko HATTORI-SHIME, Keiji OZEKI, Toshie ARAKI, Masumi MAKITA, Naomi KOBAYASHI, Hidekatsu FUKUTA, Takeshi KAMIYA |
| 2 |
[GO] |
2024―Jun―26 |
Impact of COVID-19 Pandemic on Clinical Pharmacology Trials in Japanese Subjects Conducted at Phase 1 Units in Japan or Overseas |
Saori TSUCHIYA, Chieko MUTO, Shinji TATAMI, Megumi FURUKAWA, Tong ZHU, Sandhya GIRISH, et al. (+2) Hiroyuki YOSHITSUGU, Lee NAGAO |
| 3 |
[GO] |
2024―Feb―22 |
Issues and Challenges Regarding the Conduction of Novel Coronavirus Vaccine Clinical Trials","新型コロナウイルスワクチン試験の実施での問題点と課題 |
Takashi ETO, Miwa HARANAKA, Noritomo IZUMI, Koki FURUSHO, Yuka TABUCHI, Yuko KISHIMOTO, et al. (+6) Akane YAMADA, Yuko SAKATA, Erika RYU, Misato NAGAMIZU, Satsuki KANEMITSU, Shin IRIE |
| 4 |
[GO] |
2022―Dec―21 |
Study Protocol for a Randomized Double-blind Placebo-controlled Phase 2 Clinical Trial to Assess Anti-inflammatory Effect of Colchicine (DRC3633) in Mild to Moderately Severe COVID-19 Patients (DRC-06C) |
Takeshi KINJO, Yumi IKEHARA, Toshihiro MISUMI, Kouji YAMAMOTO, Kenta MUROTANI, Takashi OGURA, et al. (+2) Toshio MIYATA, Shin-ichiro UEDA |
| 5 |
[GO] |
2021―Jun―22 |
COVID-19 Pandemic as an Opportunity to Transform Drug Development |
Taro ISHIBASHI, Michiyo OHSHIMA, Takayuki IMAEDA, Norisuke KAWAI |
|
